FDI Clinical Research | San Juan, PR

Research site

(Unclaimed)

Location

998 Munoz Rivera Avenue, San Juan, Puerto Rico, United States of America

Site insights

Top conditions

Top treatments

Bevacizumab

Pembrolizumab

Nivolumab

Resmetirom

MK-3655-001

Capecitabine

ION224

cemiplimab

Semaglutide

Letrozole

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 30 total trials

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling

Non-alcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study of Distal Jejunal-release Dextrose in Obese Participants

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in ob...

Enrolling

Obese

Drug: APHD-012

Drug: APHD-012P

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Enrolling

Carcinoma, Hepatocellular

Drug: Relatlimab

Drug: Bevacizumab

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has fail...

Enrolling

Breast Cancer Stage IV

Breast Cancer

Drug: MBQ-167

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Enrolling

Type 2 Diabetes

Drug: Orforglipron

Drug: Placebo

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)

The primary purpose of this study is to assess the efficacy and safety of the etonogestrel (ENG) contraceptive implant during participants' fourth an...

Active, not recruiting

Contraception

Combination Product: Radiopaque Etonogestrel (ENG) Implant

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling

Advanced Breast Cancer

Drug: Fulvestrant

Drug: ARV-471

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Enrolling

Arthritis, Psoriatic

Drug: Placebo

Drug: Guselkumab

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling

Solid Tumors

Hematologic Malignancies

Drug: Pembrolizumab

Drug: Lenvatinib

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+,...

Enrolling

Breast Cancer

Drug: Anastrozole Tablets

Drug: Tamoxifen

Locations recently updated

Pan Tumor Rollover Study

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tum...

Enrolling

Cancer

Drug: Temozolomide

Drug: Capecitabine

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo (NNC0194-0499)

Drug: NNC0174 0833 placebo

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal...

Invitation-only

Breast Cancer

Drug: Exemestane Tablets

Drug: Anastrozole Tablets

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling

Asthma

Drug: Placebo

Drug: Dupilumab

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Docetaxel

Drug: DS-1062a

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adu...

Active, not recruiting

Neoplasms, Head and Neck

Metastatic Head and Neck Cancer

Combination Product: Pembrolizumab (KEYTRUDA®) and PDS0101

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting

Nonalcoholic Steatohepatitis

Drug: PTM CILO/FIR

Drug: Cilofexor (CILO)/Firsocostat (FIR)